MA
RYTM icon

Montag & Associates’s Rhythm Pharmaceuticals RYTM Stock Holding History

Montag & Associates’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$564 Buy
+5
New +$452 ﹤0.01% 942

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Montag & Associates's RYTM Position: Q2 2026 in Review

Montag & Associates opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 5 shares worth $564. The stake represents ﹤0.01% of the portfolio and ranks #942 among its holdings.

303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Montag & Associates held 5 shares of Rhythm Pharmaceuticals worth $564 as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Montag & Associates position in Q2 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Montag & Associates's portfolio in Q2 2026, its #942 holding.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.